Goldman Sachs’s Aegerion Pharmaceuticals AEGR Stock Holding History

Goldman Sachs’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-61,700	Closed	-$623K	–	7522
2015 Q4	$623K	Buy	+61,700	New	+$743K	﹤0.01%	4727
2015 Q2	–	Sell	-1,500	Closed	-$39K	–	7584
2015 Q1	$39K	Buy	+1,500	New	+$38.2K	﹤0.01%	6771
2014 Q4	–	Sell	-49,500	Closed	-$1.65M	–	7469
2014 Q3	$1.65M	Sell	49,500 -500	-1%	-$15.5K	﹤0.01%	4115
2014 Q2	$1.6M	Sell	50,000 -308,900	-86%	-$11.5M	﹤0.01%	4214
2014 Q1	$16.6M	Buy	358,900 +348,900	+3,489%	+$20.5M	0.01%	1927
2013 Q4	$710K	Buy	+10,000	New	+$765K	﹤0.01%	5030

Goldman Sachs's AEGR Position: Q4 2016 in Review

Goldman Sachs sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 218,481 shares — an estimated $649K sold.

Goldman Sachs first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $18.6M in Q4 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Goldman Sachs reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Goldman Sachs sold 218,481 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $649K.
Goldman Sachs first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Goldman Sachs's Aegerion Pharmaceuticals position peaked at $18.6M in Q4 2014.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.